# GILT Docetaxel - Non-Small Cell Lung Cancer

> **NCT00174629** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 449 (actual)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** Docetaxel/DDP
- **DRUG:** docetaxel/gemcitabine

## Key facts

- **NCT ID:** NCT00174629
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 449 (ACTUAL)
- **Last updated:** 2009-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00174629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00174629, "GILT Docetaxel - Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT00174629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*